Eli Lilly continues clinical research in September 2026
Between September 14 and September 29, 2026, Eli Lilly conducted several clinical trials, including studies of new compounds and the completion of a Phase 4 trial for diabetes treatment. These activities aim to assess the therapeutic potential of experimental agents and new indications for existing drugs.
Key points
- The company conducted Phase 1 studies for several new compounds.
- The studies involve patients with various conditions, including cancer, diabetes, and alopecia.
Clinical trials and completed studies.
The company conducted Phase 1 studies for several new compounds. The LY4064912 study enrolled 77 participants, the LY4057996 trial expects 124 individuals, and the eloralintide study aims to enroll 58 participants.
During this period, a Phase 4 trial involving 153 patients with type 2 diabetes was completed. The study evaluated the combination of insulin lispro and insulin glargine.
Participants in studies.
The studies involve patients with various conditions, including cancer, diabetes, and alopecia. In particular, a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia was completed, where 17 of 27 participants completed the full 52-week therapy course.
Next steps in drug assessment.
Further analysis of results and updates to trial registries will help determine the prospects of these developments. The success of bringing new drugs to market depends on meeting regulatory milestones and proving safety and efficacy.
Original sources
- NCT03531645: Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma (ACTIVE_NOT_RECRUITING)
- NCT07152002: A Study of LY4064912 in Healthy Participants and With Overweight or Obesity (TERMINATED)
- NCT06370715: A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (COMPLETED)
- NCT07843732: Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent (COMPLETED)
- NCT06945406: A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes (RECRUITING)
- NCT07701083: A Study of Eloralintide (LY3841136) in Healthy Participants (ACTIVE_NOT_RECRUITING)
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow ELI Lilly
A notification in your browser or on your phone when we publish about ELI Lilly. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
